Form 144 COLLEGIUM PHARMACEUTICAL For: 17 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Collegium Pharmaceutical Inc (COLL)
Collegium Pharmaceutical Inc stock price live, this page displays NASDAQ COLL stock exchange data. View the COLL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Collegium Pharmaceutical Inc real time stock price chart below.
What Is the Collegium Pharmaceutical Inc Stock Price Today?
The Collegium Pharmaceutical Inc stock price today is 36.08.
What Is the Stock Symbol for Collegium Pharmaceutical Inc?
The stock symbol for Collegium Pharmaceutical Inc is "COLL."
What Stock Exchange Does Collegium Pharmaceutical Inc Trade On?
Collegium Pharmaceutical Inc is listed and trades on the NASDAQ stock exchange.
Is Collegium Pharmaceutical Inc a Good Stock to Buy?
Determining whether Collegium Pharmaceutical Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the COLL quote. (ISIN: US19459J1043)
What Is the Collegium Pharmaceutical Inc Stock Price Today?
The Collegium Pharmaceutical Inc stock price today is 36.08.
What Is the Stock Symbol for Collegium Pharmaceutical Inc?
The stock symbol for Collegium Pharmaceutical Inc is "COLL."
What Stock Exchange Does Collegium Pharmaceutical Inc Trade On?
Collegium Pharmaceutical Inc is listed and trades on the NASDAQ stock exchange.
Is Collegium Pharmaceutical Inc a Good Stock to Buy?
Determining whether Collegium Pharmaceutical Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the COLL quote. (ISIN: US19459J1043)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
35.50
36.93
52 wk Range
29.19
50.79
Earnings results expected in 11 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
35.5036.93
52 wk Range
29.1950.79
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
COLL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
53.60
Upside
+48.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- Form 13G Collegium Pharmaceutical For: 12 May
- Investing.com
- Form 8K Collegium Pharmaceutical For: 12 May
- Investing.com
- Form 144 COLLEGIUM PHARMACEUTICAL For: 15 May
- Investing.com
- Form 144 COLLEGIUM PHARMACEUTICAL For: 17 July
- Investing.com
- Form 144 COLLEGIUM PHARMACEUTICAL For: 15 May
- Investing.com
- Form 144 COLLEGIUM PHARMACEUTICAL For: 13 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 53.60
(+48.56% Upside)
Collegium Pharmaceutical Inc Earnings Call Summary for Q1/2026
- Q1 2026 EPS of $1.76 beat estimates of $1.63 by 7.98%; revenue rose 9% YoY to $193.5M, exceeding forecast of $187.37M
- Jornay PM drove growth with 36% revenue increase; non-GAAP adjusted EBITDA climbed 9% YoY to $103.9M; GAAP net income surged 500%
- Company announced strategic acquisition of AZSTARYS to strengthen ADHD market position; deal expected to be immediately accretive to EBITDA
- Full-year revenue guidance maintained at $805M-$825M excluding AZSTARYS impact; FY2026 EPS projected at $9.39
- Stock rose 3.53% in pre-market trading to $37.80; market cap stands at $1.14B with P/E ratio of 21.36
Last Updated: 2026-05-13, 01:30 p/m
Read Full TranscriptEarnings
Latest Release
May 07, 2026
EPS / Forecast
1.76 / 1.63
Revenue / Forecast
193.52M / 187.37M
Compare COLL to Peers and Sector
Metrics to compare | COLL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCOLLPeersSector | |
|---|---|---|---|---|
P/E Ratio | 15.6x | −0.7x | −0.4x | |
PEG Ratio | 0.51 | 0.00 | 0.00 | |
Price/Book | 3.7x | 1.4x | 2.6x | |
Price / LTM Sales | 1.5x | 1.8x | 3.0x | |
Upside (Analyst Target) | 55.2% | 120.3% | 53.5% | |
Fair Value Upside | Unlock | 8.4% | 9.0% | Unlock |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Collegium Pharmaceutical (COLL) Stock Price Today?
The Collegium Pharmaceutical stock price today is 36.08 USD.
What Stock Exchange Does Collegium Pharmaceutical Trade On?
Collegium Pharmaceutical is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Collegium Pharmaceutical?
The stock symbol for Collegium Pharmaceutical is "COLL."
What Is the Collegium Pharmaceutical Market Cap?
As of today, Collegium Pharmaceutical market cap is 1.17B USD.
What Is Collegium Pharmaceutical's Earnings Per Share (TTM)?
The Collegium Pharmaceutical EPS (TTM) is 1.64.
When Is the Next Collegium Pharmaceutical Earnings Date?
Collegium Pharmaceutical will release its next earnings report on Jul 30, 2026.
From a Technical Analysis Perspective, Is COLL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Collegium Pharmaceutical Stock Split?
Collegium Pharmaceutical has split 0 times.
How Many Employees Does Collegium Pharmaceutical Have?
Collegium Pharmaceutical has 423 employees.
What is the current trading status of Collegium Pharmaceutical (COLL)?
As of Jul 19, 2026, Collegium Pharmaceutical (COLL) is trading at a price of 36.08 USD, with a previous close of 36.27 USD. The stock has fluctuated within a day range of 35.50 USD to 36.93 USD, while its 52-week range spans from 29.19 USD to 50.79 USD.
What Is Collegium Pharmaceutical (COLL) Price Target According to Analysts?
The average 12-month price target for Collegium Pharmaceutical is 53.60 USD, with a high estimate of 60 USD and a low estimate of 45 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +48.56% Upside potential.
What Is the COLL Premarket Price?
COLL's last pre-market stock price is 36.97 USD. The pre-market share volume is 70.00, and the stock has decreased by 0.70, or 1.93%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.